Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2-breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01958021
What this trial is testing

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

Who this might be right for
Advanced, Metastatic Breast Cancer
Novartis Pharmaceuticals 668
Not applicableUnknownNCT05544123
What this trial is testing

The Treatment Situation of Chinese County Population With Breast Cancer

Who this might be right for
Breast CancerBreast CarcinomaBreast Tumor
The First Affiliated Hospital of Xinxiang Medical College 2,500
Large-scale testing (Phase 3)Looking for participantsNCT07461454
What this trial is testing

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
MediLink Therapeutics (Suzhou) Co., Ltd. 376
Large-scale testing (Phase 3)Study completedNCT05375461
What this trial is testing

TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

Who this might be right for
HR-positive,HER2-negative in Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 293
Testing effectiveness (Phase 2)Looking for participantsNCT07810088
What this trial is testing

Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer

Who this might be right for
HR+ / HER2- Advanced Breast Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 40
Large-scale testing (Phase 3)Study completedNCT03462251
What this trial is testing

Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line

Who this might be right for
Breast CancerHormone Receptor Positive TumorHER 2 Negative Breast Cancer
iOMEDICO AG 41
Testing effectiveness (Phase 2)UnknownNCT05749575
What this trial is testing

Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.

Who this might be right for
Breast Cancer
Sun Yat-sen University 28
Not applicableStudy completedNCT07498413
What this trial is testing

Epidemiology and Treatment of HR+/HER2- Breast Cancer in England

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 218,677
Large-scale testing (Phase 3)Looking for participantsNCT07190443
What this trial is testing

Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)

Who this might be right for
Breast CancerLocoregional RecurrenceAbemaciclib+1 more
Japanese Foundation for Cancer Research 290
Large-scale testing (Phase 3)Study completedNCT02422615
What this trial is testing

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 726
Large-scale testing (Phase 3)Active Not RecruitingNCT05038735
What this trial is testing

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 210
Testing effectiveness (Phase 2)Looking for participantsNCT05872347
What this trial is testing

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Who this might be right for
Breast Cancer Brain Metastases
Shanghai Pharmaceuticals Holding Co., Ltd 52
Not applicableLooking for participantsNCT07476170
What this trial is testing

Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China

Who this might be right for
HR+/HER2- Advanced or Metastatic Breast Cancer
Novartis Pharmaceuticals 14,000
Large-scale testing (Phase 3)Active Not RecruitingNCT04639986
What this trial is testing

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Who this might be right for
Metastatic Breast Cancer
Gilead Sciences 331
Testing effectiveness (Phase 2)UnknownNCT05885776
What this trial is testing

Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 48
Testing effectiveness (Phase 2)Looking for participantsNCT07383818
What this trial is testing

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

Who this might be right for
HR Positive/HER2 Low Breast Cancer
First Affiliated Hospital of Zhejiang University 111
Large-scale testing (Phase 3)Temporarily pausedNCT05503108
What this trial is testing

Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer

Who this might be right for
Fasting Mimicking DietHER2-negative Breast CancerHormone Receptor-positive Breast Cancer+3 more
Leiden University Medical Center 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07782840
What this trial is testing

QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy

Who this might be right for
Breast Cancer
Hebei Medical University Fourth Hospital 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06592625
What this trial is testing

Neoadjuvant SHR-A1811 Plus Adebrelimab in HR Negative/Low & HER2 Low Breast Cancer Patients

Who this might be right for
Untreated Early-stage or Locally Advanced Breast Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 60
Testing effectiveness (Phase 2)Looking for participantsNCT05759546
What this trial is testing

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Fudan University 200
Next Page